 | | Vol. 11.45 – 14 December, 2022 |
| |
|
|
| Researchers identified nuclear prelamin A recognition factor (NARF) as a hypoxia-inducible, hypoxia-inducible factor 1 target gene in human breast cancer cells.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified binding targets of Musashi-1 in normal neural and group 3 medulloblastoma stem cells and then cross referenced these data with unbiased large-scale screens at the transcriptomic, translatomic, and proteomic levels.
[Nature Communications] |
|
|
|
| Investigators showed that Hoxa9/Meis1-dependent AML was hierarchically organized and tracked the developmental potential of leukemic stem cell phenotypes.
[Leukemia] |
|
|
|
| Scientists demonstrated that the F-box protein FBXL2 was a critical negative regulator of breast cancer stem cell stemness and that downregulation of FBXL2 played a causal role in TNBC drug resistance.
[Oncogene] |
|
|
|
| Researchers clarified a new oncogenic mechanism of enhancer of Zeste Homolog 2 (EZH2) by which it interacted with heterochromatin protein 1 binding protein 3 (HP1BP3) and epigenetically activated WNT7B thereby promoting TMZ resistance in glioma stem cells.
[Oncogene] |
|
|
|
| To characterize protein expression in glioblastoma CSCs (GSCs), scientists performed in-depth proteogenomic analysis of patient-derived GSCs by RNA-sequencing and mass-spectrometry.
[Molecular Oncology] |
|
|
|
| The authors established two highly malignant glioma stem-like cell (GSC) lines from clinical surgical specimens and found that the long non-coding RNA growth arrest-specific 5 (GAS5) expression was downregulated in GSCs and high-grade glioma tissues.
[Cancer Gene Therapy] |
|
|
|
| Based on the cytotoxic properties of aporphine compounds, researchers evaluated the biological effect of 12 compounds obtained through total synthesis of (±)-apomorphine hydrochloride against glioblastoma cells.
[Scientific Reports] |
|
|
|
| Scientists reported that triiodothyronine exerted significant impact on CSCs of two colorectal cancer cell lines cultured in the form of colonospheres.
[Oncology Reports] |
|
|
|
| Investigators identified a role for Twist-related protein 1 (TWIST1) in the establishment of esophageal squamous cell carcinoma CSC-like phenotype, facilitating the transformation of non-CSCs to CSCs.
[BMC Cancer] |
|
|
|
|
| Scientists review the progress made in understanding biological features of circulating tumor cells and provide insight into exploiting these developments to design future clinical tools
[Nature Reviews Cancer] |
|
|
|
| The authors discuss CSCs, radioresistance-mediated CSCs development, epithelial-to-mesenchymal transition associated with CSCs, the role of exosomes in radioresistance development, and the current state of radiation therapy.
[Biomarkers] |
|
|
|
|
| Calidi Biotherapeutics, Inc. announced that the CIRM has awarded the company a $3.1 million grant to support the continued development of the company’s Supernova-1 pre-clinical program through an Investigational New Drug application.
[Calidi Biotherapeutics, Inc.] |
|
|
|
|
| February 19 – 22, 2023
New Orleans, Louisiana, United States |
|
|
|
|
|
| | Rutgers Biomedical and Health Sciences – Newark, New Jersey, United States |
|
|
|
| | Westlake University – Hangzhou, China |
|
|
|
| | Flanders Institute for Biotechnology – Leuven, Belgium |
|
|
|
| | University of California Irvine – Irvine, California, United States |
|
|
|
| | Novartis – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
